Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

blasedp31 25 posts  |  Last Activity: Aug 12, 2015 9:28 PM Member since: Jan 16, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Looking for information about Insmed?

    by insmhistorian Aug 12, 2015 10:12 AM
    blasedp31 blasedp31 Aug 12, 2015 9:28 PM Flag

    Omigosh Terry, the sky is falling!! Prove it!!

  • Reply to

    Blasedp31......could you please clarify.....

    by insmhistorian Aug 9, 2015 2:15 PM
    blasedp31 blasedp31 Aug 9, 2015 4:27 PM Flag

    Historian. I don't know if i can connect any dots, other than Pauls was with Insmed previously. I guess the only connection is that both executives are thinking about the bottom line when the time comes, and taking advantage of the Irish tax situation to potentially increase future revenues. Higher future revenues would translate into a potentially higher stock price. I think Shire would have an interest in Insmed down the road should the EMA grant a favorable ruling for Arikayce.

  • Reply to

    As we have said before...

    by x10bagger Aug 6, 2015 1:53 PM
    blasedp31 blasedp31 Aug 7, 2015 6:19 PM Flag

    I believe they sold, leased, or closed it.

  • From Fierce Biotech
    After a hectic period in which every biopharma seemed to be seeking to relocate its way to a lower tax rate, the furor over who pays what and where has died down a little in recent months. But the number crunchers are still working away in the background--and in the case of Cortendo they are on the cusp of engineering a move to Ireland.

    Cortendo CEO Matthew Pauls
    If the plan comes to fruition, the Swedish-American drugmaker will add Ireland to its list of locations by having a public limited company it has set up on the Emerald Isle acquire the rest of the business. The Ireland-based operation would then become the parent company, with the business as it stands today assuming the status of a subsidiary. Cortendo could still pull out of the geographic reshuffle, but it has done the sums and sees a move to Ireland as attractive for the same reason as every other multinational: taxes.

    In a release to outline the plan, Cortendo refers to "tax-efficient allocations of capital," "tax-efficient returns of capital to shareholders" and the ability to operate "more flexibly and efficiently" as the motivations for the move. Over the past year, Ireland has attempted to dispel the impression that it is a tax haven--notably by committing to phasing out the "Double Irish" scheme--but it still wants to use its rates as a way to attract businesses. The phasing out of the Double Irish scheme coincided with a reaffirmation of Ireland's commitment to a 12.5% tax rate and outlining of a patent box plan

  • Reply to

    Tomorrow

    by dorianrivers21 Aug 5, 2015 9:36 AM
    blasedp31 blasedp31 Aug 5, 2015 9:11 PM Flag

    Maybe Insmed might mention another product they are interested in purchasing!

  • Reply to

    If you would look

    by zake1 Jul 29, 2015 7:33 AM
    blasedp31 blasedp31 Jul 29, 2015 8:05 AM Flag

    I think the FOS Loser is only doing his job to distort, manipulate facts, and outright lie. He has to gain something for his BS efforts.

  • Tuberculosis (TB) Treatment
    Can't help but think that Insmed will consider Arikayce will be more helpful than the injectable amikacin for TB patients:

    With appropriate antibiotic treatment, TB can be cured in most people. Successful treatment of TB depends on close cooperation between patients and healthcare providers. Treatment usually involves taking several antibiotic drugs for at least 6 months and sometimes for as long as 12 months.

    Antibiotic Resistance and the Importance of Finishing the TB Medicine

    People who do not take all the required medicines can become sick again and spread TB to others. Additionally, when people do not take all the prescribed medicines or skip times when they are supposed to take them, the TB bacteria evolve to outwit the TB antibiotics. Soon those medicines no longer work against the disease. If this happens, the person now has drug-resistant TB. Additionally, some people with TB do not get better with treatment because their disease is caused by a strain of the TB bacterium that is already resistant to one or more of the standard TB drugs.

    Multidrug-resistant TB (MDR TB) is TB that is resistant to at least two of the best Food and Drug Administration-approved anti-TB drugs, isoniazid and rifampicin. These antibiotics are considered first-line drugs and are the first medicines used to treat all persons with TB disease. Extensively drug-resistant TB (XDR TB) is a relatively rare type of TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (such as amikacin, kanamycin, or capreomycin). Worldwide, TB drug resistance is on the rise. In 2010, the World Health Organization estimated that more than 650,000 people have MDR TB.

  • blasedp31 blasedp31 Jul 27, 2015 1:41 PM Flag

    If this was Pictionary, we would need a picture of Terry with his surf board as Insmed's resident basher!!

  • The PRAC minutes had this on page 66:

    Medicines in the pre-authorisation phase:

    As per agreed criteria, the PRAC endorsed without further plenary discussion the conclusions of the Rapporteur on the assessment of the RMP for the below mentioned medicines under evaluation for initial marketing authorisation application. Information on the medicines containing the below listed active substance will be made available following the CHMP opinion on their marketing authorisation(s):

    14.1.1. Amikacin - EMEA/H/C/003936, Orphan Applicant: Insmed Limited Scope: Treatment of nontuberculous mycobacterial (NTM) lung infections in adult patients and management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older

  • blasedp31 blasedp31 Jul 22, 2015 5:30 PM Flag

    Jad, Don't know the exact timetable, but I would guess we are near or past the 150 Day Mark where the Rappoteurs would give their Assessment Report. The PRAC endorsed the conclusions of the Rappoteurs' assessment on July 8 it appears, so maybe that was Day 150. Now it seems its up to the CHMP Committee to make more comments, ask questions, need answers. If they don't, I guess they can make a decision in August or September.

  • The PRAC minutes had this on page 66:

    Medicines in the pre-authorisation phase:

    As per agreed criteria, the PRAC endorsed without further plenary discussion the conclusions of the Rapporteur on the assessment of the RMP for the below mentioned medicines under evaluation for initial marketing authorisation application. Information on the medicines containing the below listed active substance will be made available following the CHMP opinion on their marketing authorisation(s):

    14.1.1. Amikacin - EMEA/H/C/003936, Orphan Applicant: Insmed Limited Scope: Treatment of nontuberculous mycobacterial (NTM) lung infections in adult patients and management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older

  • Reply to

    The silence is telling

    by dorianrivers21 Jul 14, 2015 8:36 AM
    blasedp31 blasedp31 Jul 14, 2015 11:03 AM Flag

    JD. That's Terry fake clone ID job. His day is coming, and he won't be ready. He is not who he says he is.

  • Reply to

    iPlex.....

    by insmhistorian Jul 7, 2015 7:50 PM
    blasedp31 blasedp31 Jul 7, 2015 8:41 PM Flag

    I saw where United Healthcare had Iplex listed in their drug formulary but it was considered a special pharmaceutical order. Don't know where they get it, but it counters numbnuts assertions that Iplex is dead. Why would Aetna and United Healthcare list it in their drug formularies if it wasn't an approved drug. Maybe they will fill the prescription in 2017 or 2018 when it comes off the court settlement agreement, and it will have some value to some entity. So my conclusion, is that it's NOT dead, and it's value will only get more as we approach the settlement date, licensing agreements, or outright sale. It's almost similar to an extraordinary pro athlete who has been signed to a bare minimum contract due to pro labor laws, but when free agency arrives for him. his value will explode when he has many more potential suitors.

    Fasten your seatbelts..................... 2017 is just around the corner!! How much lead time will Iplex handlers need to get it to market. 12 to 18 months??

  • blasedp31 blasedp31 Jul 6, 2015 7:42 PM Flag

    You should know Terry, you are the king of idiot posts!! Loser!

  • blasedp31 blasedp31 Jun 23, 2015 3:29 PM Flag

    Check tonight or tomorrow morning.

  • blasedp31 blasedp31 Jun 20, 2015 11:51 AM Flag

    Policy
    Aetna considers mecasermin (Increlex) and mecasermin rinfabate (Iplex)* medically necessary for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (IGFD) who meet all of the following selection criteria.

    Basal insulin-like growth factor-1 (IGF-1) standard deviation score less than or equal to -3.0 for age and sex (see Appendix); and
    Height standard deviation score less than or equal to -3.0 for age and sex (see Appendix); and
    Normal or elevated growth hormone (GH) (defined as stimulated serum GH level (peak level) of greater than 10 nanograms per milliliter (ng/ml) or basal (unstimulated) serum GH level greater than 5 ng/ml).

    * Mecasermin rinfabate (Iplex) is currently not marketed because of a court order related to patent infringement.

    It will be when the patent infringement court order is over.

    Try again, Terry

  • blasedp31 blasedp31 Jun 18, 2015 1:35 PM Flag

    Terry. you loser! I guess imitation is the sincerest form of flattery. Nice clone job!

  • blasedp31 blasedp31 Jun 18, 2015 9:48 AM Flag

    The fabrication is your phony ID Terry! Plus, all the other BS you post!

  • blasedp31 blasedp31 Jun 16, 2015 5:13 PM Flag

    Maybe Insmed could use its new found stock proceeds to buyout the court restrictions on Insmed. to move up the date. Something's better than nothing for Tercica/Genetech's purchaser especially in 2 years

  • Reply to

    Random thoughts and questions about iPlex

    by insmhistorian Jun 16, 2015 1:20 PM
    blasedp31 blasedp31 Jun 16, 2015 1:51 PM Flag

    Ok Terry. Since you feel there is no need to discuss further the Iplex equation, why don't you just butt out when someone else wants to discuss it. But you are such a FOS Loser, you won't be able to, nor will you ever be able to prove that Iplex has no value. No one here is blinded by "wanting to believe" on Iplex. They know the scenario, and it's only a possibility. The only one blinded by a "wanting to believe" is you. You are wanting to believe you and your BS ideas can make a difference!!

INSM
25.69+0.56(+2.23%)Aug 28 4:00 PMEDT